Ambrisan 5
- Ambrisan, an effective treatment for Pulmonary Arterial Hypertension (PAH) (WHO Group 1), enhances exercise capacity and delays clinical deterioration.
- A high-affinity ETA receptor antagonist, Ambrisan exhibits selectivity for the ETA receptor, promising improved outcomes for PAH management.
- With dose-proportional pharmacokinetics and a flexible dosing regimen, Ambrisan offers convenience and efficacy for adult patients.
- Safety precautions include contraindications in pregnancy and caution in hepatic impairment, ensuring comprehensive care for individuals with PAH.